Bioiberica S.A.U.
Carrer Antic Camí de Tordera, 109, 119, 08389 Palafolls, Barcelona
T: +34 93 490 49 08


Bioiberica is a global Life Science company specialised in the identification, extraction and development of biomolecules of high biological and therapeutic value for the pharmaceutical and nutraceutical industries. Over the last 40 years, this specialisation has positioned Bioiberica as the leading Heparin API manufacturer and a world reference in the research, production and sale of animal-derived APIs and ingredients. These include:

Heparin – the most used anticoagulant blood thinner globally, which now saves more than 100 million lives every year the world over.

Thyroid – natural origin thyroid API extracted from porcine thyroid glands used to treat hypothyroidism and its associated symptoms. Bioiberica’s thyroid API is entirely of European origin.

Chondroitin sulphate – used for the symptomatic treatment of osteoarthritis. Clinical trials demonstrate its effectiveness in reducing joint pain and increasing mobility.1,2 Bioiberica’s chondroitin sulphate is the chemical reference substance in the EU and US pharmacopoeias and obtained from various animal sources.

Glucosamine – used for the symptomatic treatment of mild knee osteoarthritis. Clinical trials demonstrate its ability to reduce joint pain and improve mobility.3 Glucosamine supplied by Bioiberica is produced by hydrolysis of crustacean shells.


Bioiberica’s production capacity, supply chain model and vertical integration guarantee full traceability, security and sustainability making it a trusted partner with which to grow and innovate. The company’s commitment to international standards and industrial excellence means it delivers API quality, safety and regulatory compliance too.


Bioiberica is always looking for opportunities to partner with others – to help them innovate by providing the scientific, regulatory, industrial and market expertise they need to do their best work.

To support future innovation in healthcare, Bioiberica seeks new partnerships to kickstart exciting developments in the following areas:

  • Glycosaminoglycans
  • Proteins and bioactive peptides of non-recombinant origin
  • Complex lipids
  • Other high-value biological substances




  1. Bruyère O, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63.
  2. Rillo O, et al. PANLAR Consensus Recommendations for the Management in Osteoarthritis of Hand, Hip, and Knee. J Clin Rheumatol. 2016 Oct;22(7):345-54.
  3. Ogata T, et al. Effects of glucosamine in patients with osteoarthritis of the knee: a systematic review and meta-analysis. Clin Rheumatol. 2018 Sep;37(9):2479-2487.